Ionis Pharmaceuticals vs Travere Therapeutics
IONS and TVTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IONS and TVTX compare
Ionis Pharmaceuticals and Travere Therapeutics are about the same size, with market caps of $4.7B and $4.7B.
Travere Therapeutics grew revenue faster over the last twelve months (77.1% versus −7.4% for Ionis Pharmaceuticals).
Travere Therapeutics keeps more of each dollar of sales as profit, with a net margin of −7.4% compared with −64.7% at Ionis Pharmaceuticals.
Travere Therapeutics scores higher on the StockData Score (6 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IONS | TVTX |
|---|---|---|
| Size and price | ||
| Market cap | $4.7B | $4.7B |
| Share price | $28.01 | $49.70 |
| Change, 1 year | −59.9% | 46.7% |
| Change, 5 years | −3.6% | 71.2% |
| Beta (5Y) | 0.55 | 1.95 |
| Employees | 1,402 | 497 |
| StockData Score | ||
| Total score | 4 | 6 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.3× (better) | 7.9× |
| P/B | 10.6× (better) | 191× |
| EV/EBITDA | – | 192× |
| FCF yield | −12.0% | – |
| Fair value | $28.16 | $6.04 |
| Margin of safety | 0.55% (better) | −723% |
| Growth | ||
| Revenue growth (TTM) | −7.4% | 77.1% (better) |
| Revenue growth, 5Y average | 5.3% | 19.9% (better) |
| Profitability | ||
| Gross margin | 98.2% | 98.6% (better) |
| Operating margin | −68.0% | −6.8% (better) |
| Net margin | −64.7% | −7.4% (better) |
| FCF margin | −64.2% | – |
| Return on equity | −105% (better) | −152% |
| Financial health | ||
| Interest coverage | −31.6× | −4.3× (better) |
| Current ratio | 7.89 (better) | 4.05 |
| Altman Z-score | 0.27 | 2.19 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 108% | 112% |
| Held by insiders | 0.81% | 1.6% |
| Insider net buying, 12 months | −$114M | −$110M (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 12.8% | 10.3% |
Go deeper
- IONS stock overview
- IONS income statement
- IONS valuation and score
- TVTX stock overview
- TVTX income statement
- TVTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.